Nanox.AI vs Pearl
Nanox.AI reads CT scans a hospital already has. HealthCCSng measures coronary calcium on non-gated chest CT, HealthOST flags vertebral height loss and bone density, and HealthFLD measures liver density. Pearl reads dental radiographs and dental CBCT. A health system that wants unrecognized chronic disease flagged on routine CT is the Nanox.AI customer, and a dental practice is Pearl's, so each answers to a different budget holder.
On the Nanox side, the vendor says seven FDA clearances while openFDA lists twelve AI records under the Zebra, Nanoxai and Nano-X AI names, and the AI page presents three current solutions. A 2025 HealthOST validation reported 92.0% sensitivity at the 20% height-loss threshold, with the abstract's specificity figures beginning at 52.7%.
Pearl's FAQ names the systems it connects to, among them DEXIS, Carestream, Romexis, Open Dental and Eaglesoft. Second Opinion 3D, cleared in May 2025 as K243989, marks dentition, the maxillary sinus and the inferior alveolar canal on CBCT.
Radiology · Reviewed November 2, 2026

Nanox.AI
by Nano-X Imaging
CT AI for opportunistic screening: coronary calcium, vertebral fractures and liver fat on routine CT scans, for radiology departments.

Pearl
by Pearl Inc. · founded 2019
FDA-cleared dental x-ray AI (Second Opinion) that marks caries, bone loss and restorations, for dentists and DSOs.
When to pick each one
Nanox.AI
- Coronary calcium, vertebral fracture and liver fat on CT
- Twelve openFDA AI records under Zebra and Nanox names
Pearl
- Names DEXIS, Carestream, Open Dental and Eaglesoft
- Dental CBCT review, K243989 May 2025
Score
Each row shows points earned of points available under the published rubric.
Nanox.AI
35of 100
Pearl
33of 100
| Dimension | Nanox.AI | Pearl | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 18.2 | 0 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 3 / 12 | +5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 4.2 / 6 | -4.2 |
Scroll horizontally to see every column.
Pricing
Nanox.AI
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Pearl
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Nanox.AI
FDA decisions
K241440 (opens in new tab)510(k)2024-08-19
HealthCCSng
K233080 (opens in new tab)510(k)2024-02-08
HealthFLD
K213944 (opens in new tab)510(k)2022-04-22
HealthOST
K211803 (opens in new tab)510(k)2021-12-15
HealthPPT
K210085 (opens in new tab)510(k)2021-09-15
HealthCCSng
Show 7 more
K202487 (opens in new tab)510(k)2020-12-04
HealthJOINT
K200905 (opens in new tab)510(k)2020-07-16
HealthMammo
K192901 (opens in new tab)510(k)2020-05-12
HealthVCF
K192320 (opens in new tab)510(k)2019-11-26
HealthCXR
K190424 (opens in new tab)510(k)2019-06-13
HealthICH
K190362 (opens in new tab)510(k)2019-05-06
HealthPNX
K172983 (opens in new tab)510(k)2018-06-13
HealthCCS
Pearl
FDA decisions
K250525 (opens in new tab)510(k)2025-11-14
Second Opinion Panoramic
K243234 (opens in new tab)510(k)2025-06-12
Second Opinion CS
K243989 (opens in new tab)510(k)2025-05-23
Second Opinion 3D
K243230 (opens in new tab)510(k)2025-05-09
Second Opinion BLE
K243893 (opens in new tab)510(k)2025-05-05
Second Opinion Pediatric
Show 3 more
K242600 (opens in new tab)510(k)2025-04-11
Second Opinion Periapical Radiolucency Contours
K242522 (opens in new tab)510(k)2025-01-16
Second Opinion CC
K210365 (opens in new tab)510(k)2022-03-04
Second Opinion
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Nanox.AI | Pearl |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | 2019 |
| HQ | n/a | US |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.
